Edap Tms SA (NASDAQ:EDAP) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price objective of $6.50 for the company and are forecasting that the company will post $0.01 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Edap Tms an industry rank of 90 out of 255 based on the ratings given to its competitors.
Several analysts have issued reports on EDAP shares. Zacks Investment Research raised Edap Tms from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Thursday, January 3rd. HC Wainwright reissued a “buy” rating and set a $6.50 price target on shares of Edap Tms in a report on Wednesday, April 3rd. ValuEngine raised Edap Tms from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, TheStreet raised Edap Tms from a “d+” rating to a “c-” rating in a report on Thursday, February 14th.
A hedge fund recently bought a new stake in Edap Tms stock. Naples Global Advisors LLC acquired a new stake in Edap Tms SA (NASDAQ:EDAP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,500 shares of the medical equipment provider’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.07% of the company’s stock.
Shares of EDAP opened at $5.13 on Wednesday. Edap Tms has a one year low of $1.35 and a one year high of $5.42. The firm has a market capitalization of $152.52 million, a P/E ratio of 256.50 and a beta of 1.60.
Edap Tms (NASDAQ:EDAP) last released its quarterly earnings results on Monday, April 1st. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter. Edap Tms had a positive return on equity of 3.77% and a negative net margin of 0.93%. The business had revenue of $15.11 million during the quarter, compared to analyst estimates of $11.74 million. On average, analysts forecast that Edap Tms will post 0.11 EPS for the current fiscal year.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Featured Article: What are the FAANG Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.